Current overview of relevant molecular biomarkers in molecular pathology
We offer a wide range of therapy-relevant genetic testing for solid tumors.
The information serves as a guide to molecular biomarkers and targeted drugs. Due to the complexity of study results and drug approvals, the completeness of the data cannot be guaranteed. Drug treatment can only be initiated by qualified oncologists, usually based on tumor board decisions.
Genes
AKT1
AKT1
AKT1
ALK
ALK
ALK
ALK
ALK
ALK
ALK
ATM
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRAF
BRCA1 / BRCA2
BRCA1 / BRCA2
BRCA1 / BRCA2
BRCA1 / BRCA2
BRCA1 / BRCA2
CTNNB1
EGFR *
EGFR *
EGFR *
EGFR *
EGFR *
EGFR *
ERBB2
ERBB2
ERBB2
ERBB2
ERBB2
ERBB2
ESR1
FGFR2
FGFR2
FGFR2
FGFR3
FGFR3
FGFR3
Homologous Recombination Deficiency
HRAS
IDH1
IDH2
KIT
KIT
KIT
KRAS
MAP2K1
MAP2K1
MAP2K1
MET
MET
MET
MET
MET
MET
MET
Mikrosatelliten-instabilität
MTOR
MTOR
MTOR
NRAS
NTRK1
NTRK1
NTRK2
NTRK3
NTRK3
PDGFRA
PDGFRA
PDGFRA
PDGFRA
PIK3CA
PIK3CA
PTEN
RET
RET
RET
ROS1
Tumor Mutation Burden
Change
Mutation E17K
Mutation E17K
Mutation E17K
Mutation, Fusion, Amplifikation
Mutation C1156Y
Mutation I1171N
Mutation L1196M
Mutation G1202R
Mutation G1269A
Fusions
Mutation (V600E)
Mutation (V600)
Mutation G464, G469, L597, K601
K601
Fusions
Fusions
Inactivating variants
Mutation
Activating mutations (e.g., exon 19 deletions, L858R, etc.)
Exon 20 Insertion, T790M
T790M
Exon 20 Insertion
D761Y
C797
Amplifications
Amplifications
Amplifications
Activating mutations
Activating mutations
Mutations
Fusions
Fusions
Activating mutations
Fusions
Activating mutations
Activating mutations
Genomic instability (HRD score high)
Activating mutations
Activating mutations
Activating mutations, Deletions, Duplications
Mutations V654A, T670I, C809G, D816, D820, N822, Y823D, A829P
Activating mutations
Activating mutations
Exon14 splice Mutation and Deletion, activating point mutations such as Y1003, D1010
Amplifikation
Amplifikation
Punkmutation D1228N
Punkmutation Y1230H
Amplifications
Fusions
MSI high
L1460P, L2209V, L2427Q
E2014K E2419K
Activating mutations
Activating mutations
Fusions
G595R
Fusions
Fusions
G623R
Activating mutations, Deletions, Duplications
D842V
D842V
D842Y, D842_H845del, D842_H845insV
Activating mutations
Activating mutations
Inactivating mutations
Activating mutations
Fusions
Fusions
Fusions
TMB high (>10 mut/Mb)
Common tumor types
Breast cancer
Endometrial cancer
Ovarian cancer
Non-small cell lung cancer
Non-small cell lung cancer
Non-small cell lung cancer
Non-small cell lung cancer
Non-small cell lung cancer
Non-small cell lung cancer
Inflammatory myofibroblastic tumor
Prostate carcinoma
Colorectal carcinoma
Anaplastic thyroid carcinoma
Pleomorphic xanthoastrocytoma
Ganglioglioma
Pilocytic astrocytoma
Melanoma
Non-small cell lung carcinoma
Anaplastic thyroid carcinoma
All solid malignancies
Melanoma
Melanoma
Ovarian carcinoma
Ovarian carcinoma
Ovarian-fallopian tube-peritoneal carcinoma
Breast carcinoma
Pancreatic carcinoma
Prostate carcinoma
Desmoid fibromatosis
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Breast carcinoma
Gastric carcinoma
Serous endometrial carcinoma
Colorectal carcinoma
Breast carcinoma
Non-small cell lung carcinoma
Breast carcinoma
Bladder carcinoma
Cholangiocellular carcinoma
All solid malignancies
Bladder carcinoma
Bladder carcinoma
All solid malignancies
Ovarian, fallopian tube, peritoneal carcinoma
Squamous cell carcinoma, head and neck
Cholangiocellular carcinoma
Cholangiocellular carcinoma
Gastrointestinal stromal tumor
Gastrointestinal stromal tumor
Melanoma
Colorectal carcinoma
Melanoma
Non-small cell lung carcinoma
Low-grade serous ovarian carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Renal cell carcinoma
All solid malignancies
All solid malignancies
Renal cell carcinoma
Bladder carcinoma
All solid malignancies
Colorectal carcinoma,
All solid malignancies
All solid malignancies
All solid malignancies
All solid malignancies
All solid malignancies
Gastrointestinal stromal tumor
Gastrointestinal stromal tumor
Gastrointestinal stromal tumor
Gastrointestinal stromal tumor
Breast carcinoma
Follicular and papillary thyroid carcinoma
All solid malignancies
Medullary thyroid carcinoma
Non-small cell lung carcinoma
Thyroid carcinoma
Non-small cell lung carcinoma
All solid malignancies
Medicines approved in Germany
Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib
Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Trametinib, Vemurafenib
Dabrafenib + Trametinib
Olaparib
Rucaparib, Niraparib
Talazoparib, Olaparib
Olaparib
Olaparib
Dacomitinib, Erlotinib, Gefitinib, Osimertinib
Resistenz Afatinib, Erlotinib, Gefitinib
Osimertinib
Trastuzumab, Trastuzumab Deruxtecan, Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab, Tucatinib + Capecitabine + Trastuzumab, Ado-Trastuzumab Emtansine, Lapatinib, Neratinib
Trastuzumab
Olaparib+Bevaciumab
Imatinib, Regorafenib, Sunitinib,
Imatinib
Resistenz, Panitumumab, Cetixumab
Resistenz, Panitumumab, Cetixumab
Larotrectinib Entrectinib
Larotrectinib Entrectinib
Larotrectinib Entrectinib
Imatinib, Regorafenib, Sunitinib,
Avapritinib
Alpelisib (+ Fulvestrant)
Vandetanib
Crizotinib Entrectinib
Off label/Studies
AZD5363 (Capivasertib)
AZD5363 (Capivasertib)
AZD5363 (Capivasertib)
Afatinib, Dacomitinib, Erlotinib, Gefitinib, Pembrolizumab
Resistenz Crizotinib
Resistenz Alectinib
Resistenz Crizotinib
Resistenz Alectinib
Resistenz Crizotinib
Ceritinib, Crizotinib
Olaparib
Encorafenib + Cetuximab, Encorafenib + Panitumumab
Dabrafenib + Trametinib
Dabrafenib + Trametinib Vemurafenib + Cobimetinib
Dabrafenib + Trametinib Vemurafenib + Cobimetinib
Dabrafenib + Trametinib Vemurafenib + Cobimetinib
pembrolizumab, and vemurafenib
PLX8394
Trametinib
Cobimetinib Trametinib
Cobimetinib Trametinib
Rucaparib
diagnostischer Marker
Erlotinib, Gefitinib, Afatinib, and Osimertinib
Poziotinib
Resistenz Gefitinib
Resistenz Osimertinib
Carboplatin-Taxol Regimen + Trastuzumab
Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab
Neratinib
Ado-Trastuzumab Emtansine, Neratinib
Resistenz, anti-hormonelle Therapie
Erdafitinib, AZD4547, BGJ398, Debio1347
Pemigatinib
AZD4547, BGJ398, Erdafitinib, Debio1347
Erdafitinib, AZD4547, BGJ398, Debio1347
Erdafitinib, AZD4547, BGJ398, Debio1348
AZD4547, BGJ398, Erdafitinib, Debio1347
Niraparib
Tipifarnib
Ivosidenib
Ripretinib
Resistenz, Imatinib, Sunitinib
Cobimetinib Trametinib
Capmatinib, Crizotinib , Cabozantinib
Crizotinib
Resistenz Erlotinib Osimertinib Gefitinib
Crizotinib Cabozantinib Capmatinib
Crizotinib Cabozantinib
Cabozantinib
Crizotinib
Pembrolizumab
Temsirolimus
Everolimus
Temsirolimus, Everolimus
Resistenz Larotrectinib
Resistenz Larotrectinib
Ripretinib
Resistenz Imatinib
Dasatinib
Avapritinib
Everolimus (+ Sorafenib)
GSK2636771 AZD8186
Pralsetinib
Pralsetinib Selpercatinib Cabozantinib Vandetanib
Selpercatinib
Pembrolizumab
* Activating EGFR mutations are diverse. They are the subject of numerous studies that are constantly modifying treatment strategies for non-small cell lung cancer. It is not possible to provide a complete overview of the complex results here.
